Long‐Term Firocoxib Use in Horses
ABSTRACT Background Many horses receive firocoxib over multiple years, and studies evaluating hematologic and biochemical values in these animals are lacking. Objective To describe the hematologic and biochemical values of horses receiving long‐term firocoxib. Animals A total of 79 horses receiving...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Journal of Veterinary Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jvim.70117 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309351680933888 |
|---|---|
| author | Iuri Buzelato Carli Langdon Fielding |
| author_facet | Iuri Buzelato Carli Langdon Fielding |
| author_sort | Iuri Buzelato Carli |
| collection | DOAJ |
| description | ABSTRACT Background Many horses receive firocoxib over multiple years, and studies evaluating hematologic and biochemical values in these animals are lacking. Objective To describe the hematologic and biochemical values of horses receiving long‐term firocoxib. Animals A total of 79 horses receiving long‐term firocoxib and 153 horses not receiving long‐term firocoxib and not presenting for a specific medical problem. Methods Retrospective study comparing horses receiving firocoxib (F group) and no firocoxib (NF group). Signalment, hematologic, and biochemical values were compared between the two groups. Simple linear regression was used to evaluate the relationship between the duration of firocoxib administration and specific laboratory variables. Results Horses receiving long‐term firocoxib (F) were 19 (5–33) years as compared to 15 (1–33) years for the NF group (p < 0.0001). The most common reason for receiving firocoxib was osteoarthritis in 44/79 (56%) of the animals in the F group. Horses in the F group had a total protein concentration of 6.6 (5.8–8.0) g/dL as compared to 6.5 (5.1–8) g/dL in the NF group (p = 0.03). The sodium concentration for F horses was 139 (133–143) mmol/L as compared to 138 (129–145) mmol/L for NF horses (p = 0.01). Total white blood cell count was 6.11 (2.82–14.36) 103 cells/uL in the F group as compared to 6.46 (3.04–14.71) 103 cells/uL in the NF group (p = 0.03). None of the laboratory variables were associated with the duration of firocoxib administration. Conclusions and Clinical Importance Many horses receive firocoxib for multiple years, and equine practitioners should be aware that expected changes in laboratory values are minimal. |
| format | Article |
| id | doaj-art-f384b9b9aaba48b4bd7b14823d619b7f |
| institution | Kabale University |
| issn | 0891-6640 1939-1676 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Veterinary Internal Medicine |
| spelling | doaj-art-f384b9b9aaba48b4bd7b14823d619b7f2025-08-20T03:54:11ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762025-05-01393n/an/a10.1111/jvim.70117Long‐Term Firocoxib Use in HorsesIuri Buzelato Carli0Langdon Fielding1Loomis Basin Equine Medical Center Penryn California USALoomis Basin Equine Medical Center Penryn California USAABSTRACT Background Many horses receive firocoxib over multiple years, and studies evaluating hematologic and biochemical values in these animals are lacking. Objective To describe the hematologic and biochemical values of horses receiving long‐term firocoxib. Animals A total of 79 horses receiving long‐term firocoxib and 153 horses not receiving long‐term firocoxib and not presenting for a specific medical problem. Methods Retrospective study comparing horses receiving firocoxib (F group) and no firocoxib (NF group). Signalment, hematologic, and biochemical values were compared between the two groups. Simple linear regression was used to evaluate the relationship between the duration of firocoxib administration and specific laboratory variables. Results Horses receiving long‐term firocoxib (F) were 19 (5–33) years as compared to 15 (1–33) years for the NF group (p < 0.0001). The most common reason for receiving firocoxib was osteoarthritis in 44/79 (56%) of the animals in the F group. Horses in the F group had a total protein concentration of 6.6 (5.8–8.0) g/dL as compared to 6.5 (5.1–8) g/dL in the NF group (p = 0.03). The sodium concentration for F horses was 139 (133–143) mmol/L as compared to 138 (129–145) mmol/L for NF horses (p = 0.01). Total white blood cell count was 6.11 (2.82–14.36) 103 cells/uL in the F group as compared to 6.46 (3.04–14.71) 103 cells/uL in the NF group (p = 0.03). None of the laboratory variables were associated with the duration of firocoxib administration. Conclusions and Clinical Importance Many horses receive firocoxib for multiple years, and equine practitioners should be aware that expected changes in laboratory values are minimal.https://doi.org/10.1111/jvim.70117creatininelamenessNSAIDrenalsurgery |
| spellingShingle | Iuri Buzelato Carli Langdon Fielding Long‐Term Firocoxib Use in Horses Journal of Veterinary Internal Medicine creatinine lameness NSAID renal surgery |
| title | Long‐Term Firocoxib Use in Horses |
| title_full | Long‐Term Firocoxib Use in Horses |
| title_fullStr | Long‐Term Firocoxib Use in Horses |
| title_full_unstemmed | Long‐Term Firocoxib Use in Horses |
| title_short | Long‐Term Firocoxib Use in Horses |
| title_sort | long term firocoxib use in horses |
| topic | creatinine lameness NSAID renal surgery |
| url | https://doi.org/10.1111/jvim.70117 |
| work_keys_str_mv | AT iuribuzelatocarli longtermfirocoxibuseinhorses AT langdonfielding longtermfirocoxibuseinhorses |